Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism TRPC4 inhibitors(Short transient receptor potential channel 4 inhibitors), TRPC5 inhibitors(Short transient receptor potential channel 5 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Borderline Personality Disorder | Phase 2 | BG | 13 Nov 2020 | |
Borderline Personality Disorder | Phase 2 | DE | 13 Nov 2020 | |
Borderline Personality Disorder | Phase 2 | BE | 13 Nov 2020 | |
Borderline Personality Disorder | Phase 2 | AU | 13 Nov 2020 | |
Borderline Personality Disorder | Phase 2 | ES | 13 Nov 2020 | |
Borderline Personality Disorder | Phase 2 | JP | 13 Nov 2020 | |
Borderline Personality Disorder | Phase 2 | PL | 13 Nov 2020 | |
Borderline Personality Disorder | Phase 2 | SE | 13 Nov 2020 | |
Borderline Personality Disorder | Phase 2 | AR | 13 Nov 2020 | |
Depressive Disorder, Major | Phase 2 | US | 22 Jun 2020 |
Phase 2 | 318 | Placebo (Placebo) | hpksqpgpre(tpibacafnq) = xrirfotcuj olgdbekfcu (xznsqhvxrp, aazsztpkvc - xeyaxmekfr) View more | - | 07 Nov 2024 | ||
(BI 1358894 125 mg) | hpksqpgpre(tpibacafnq) = oehmulcsvm olgdbekfcu (xznsqhvxrp, irzrhxvzyc - swfoouogtk) View more | ||||||
Phase 2 | 390 | Placebo (Placebo) | fyebkfhcvi(dvwbzuqmdu) = yeyrcdechr khezphfvmb (kwsdiivkpg, vjtufyomof - cuyhektloz) View more | - | 30 Jan 2024 | ||
(BI 1358894 5mg) | fyebkfhcvi(dvwbzuqmdu) = syexjmmrtt khezphfvmb (kwsdiivkpg, tsbfcsozuc - waydpnenul) View more | ||||||
Phase 2 | 45 | (BI 1358894) | stcaiclwhm(kwzfsrscfb) = ymcpxmgqoi ghjccnegft (chfabhceeb, abydpyfqth - nbpxexkvak) View more | - | 11 May 2023 | ||
Placebo (Placebo) | stcaiclwhm(kwzfsrscfb) = kgcupwnibm ghjccnegft (chfabhceeb, itsuirtmir - hqrlaaxcyh) View more |